Henry Schein Completes Strategic Investment in BioHorizons
Posted on January 14, 2014
Henry Schein, Inc., announced the completion of a 60% equity investment in BioHorizons, Inc., a U.S.-based manufacturer of advanced dental implant technology and tissue regeneration products sold globally. This transaction was first announced on November 26, 2013.
Together with the Company's investment in CAMLOG Biotechnologies AG, a leading manufacturer of dental implants in Europe, Henry Schein now has important positions in the U.S. and German implant markets, as well as a growing presence in the rest of the world. The investment in BioHorizons also strengthens Henry Schein's position and product portfolio in the biologics market, which is a critical adjunct to the implant market.
"With the completion of this strategic investment in BioHorizons we have advanced our dental specialties markets business strategy and now have a stronger presence in two of the world's largest markets for dental implants," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Implant dentistry is a critical element of the profession's transition to digital dentistry, and customer demand for implants and the associated materials is expected to increase as digital processes are adopted and the patient's dental experience is enhanced."
"On behalf of the shareholders and management of BioHorizons, we are delighted with the closing of the transaction and the partnership with Henry Schein which combines BioHorizons' impressive growth with Henry Schein's global strengths," said Mortimer Berkowitz III, Chairman of BioHorizons and President of HealthpointCapital, LLC. "We look forward to working with Henry Schein and the BioHorizons team to strengthen our presence in the growing implant dentistry market by continuing to develop differentiated products for our customers."